Pimavanserin for the treatment of Parkinson's disease psychosis

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 14, 2013, Pages 1969-1975

  Friedman, Joseph H ^a,b  

^a BUTLER HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

5HT2A inverse agonist; 5HT2A receptor; Antipsychotic; Parkinson's disease psychosis; Pimavanserin

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; OLANZAPINE; PIMAVANSERIN; PLACEBO; QUETIAPINE;

ARTICLE; BIPOLAR DISORDER; DELUSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HALLUCINATION; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PHARMACODYNAMICS; PSYCHOSIS; SCHIZOPHRENIA; STEADY STATE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE; PIPERIDINES; PSYCHOTIC DISORDERS; SEROTONIN 5-HT2 RECEPTOR AGONISTS; TREATMENT OUTCOME; UREA;

EID: 84884256114     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.819345     Document Type: Article

References (42)

1. Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)- N-(1-methylpiperiden-4-yl)-N'-(4-(2- methylpropyloxy)phenylmethyl)carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine (2A)receptor inverse agonist. J Pharmacol Exp Ther 2006;317(12):910-18
2. Abbas A, Roth BL. Pimavanserin tartrate: A 5HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008;9(18):3251-9
3. Meltzer HY, Massey BW, Horiguchi M. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Curr Pharm Biotechnol 2012;13(8):1572-86
4. Price DL, Bonhaus DW, McFarland K. Pimavanserin, a 5HT2A inverse agonist, reverses psychotic-like behavior in a rodent model of Parkinson's disease. Behav Pharmacol 2011;22(7):681-92
5. Teegarden BR, Al Shamma H, Xiong Y. 5HT(2A) inverse agonists for the treatment of insomnia. Curr Top Med Chem 2008;8(11):969-76
6. Meltzer HY, Elkis H, Vanover K, et al. Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol; 2 mg/day: Comparison with reference dose risperidone, 6 mg/day. Schizophr Res 2012;141(2-3):144-52
7. Ancoli-Israel S, Vanover KE, Weiner DM, et al. Pimavanserin tartrate, a 5HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in health adult volunteers. Sleep Med 2011;12(2):134-41
8. Cummings J, Isaacson S, Mills R, et al. Antipsychotic efficacy and motor tolerability in a phase III placebocontrolled study of pimavanserin in patients with Parkinson's disease psychosis (ACP 103-020). American Academy of Neurology; San Diego, CA; 2013
9. Khilnani G, Khilnani AK. Inverse agonism and its therapeutic significance. Indian J Pharmacol 2011;43(5):492-501
10. Friedman JH. Parkinson's disease psychosis update. Behav Neurol 2013; In press
11. Weintraub D, Burn DJ. Parkinson's disease: The quintessential neuropsychiatric disorder. Mov Disord 2011;26(6):1022-31
12. Starkstein SE, Brockman S, Hayhow BD. Psychiatric syndromes in Parkinson's disease. Curr Opin Psychiatry 2012;25(6):468-72
13. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease. Report of an NINDS, NIMH work group. Mov Disord 2007;22(8):1061-8
14. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010;289(1-2):12-17
15. Dotchin CL, Jusabani A, Walker RW. Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania. Parkinsonism Relat Disord 2009;15(6):457-60
16. Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in Parkinson disease: Phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005;28(5):215-19
17. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340(10):757-63
18. Pollak P, Tison F, Rascol O, et al. Clozpaine in drug induced psychosis in Parkinson's disease: A randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75(5):689-95
19. Friedman JH, Koller WC, Lannon MC, et al. Benztropine versus clozapine for treatment of tremor in Parkinson's disease. Neurology 1997;48(4):1077-81
20. Ondo WG, Levy JK, Voung KD, et al. Olanzapine treatment for dopaminergic-hallucinations. Mov Disord 2002;17(5):1031-5
21. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients. Neurology 2000;55(6):789-94
22. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patient with Parkinson's disease. Biol Psychiatry 2002;52(5):438-45
23. Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 2009;5:327-32
24. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20(8):958-63
25. Rabey JM, Prohorov T, Miniovich A, Klein C. The effect of quetiapine in Parkinson's disease (PD] psychotic patients: A double-blind labeled study of three months duration. Mov Disord 2005;20(Suppl10):S46
26. Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson's disease but not through normalization of sleep architecture: Results of a double blind clinical-polysomnograph study. Int J Neurosci 2009;119(12):2196-205
27. Friedman JH, Berman RM, Goetz CG, et al. Open label flexible-dose pilot study of evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21(12):2078-81
28. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug induced psychosis in Parkinson's disease: Preliminary experience. Clin Neuropharmacol 2004;27(1):4-5
29. Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 2006;21(9):1538-9
30. Seeman P. Atypical antipsychotic mechanisms of action. Can J Psychiatry 2002;47(1):27-38
31. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med 2013;64:393-406
32. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: Treatment of non-motor symptoms of Parkinson's disease: Report of the Quality Standards Subcommittee of the American Academy of Neurology. 2010;74(11):924-31
33. Raja M. Clozapine safety 35 years later. Curr Drug Saf 2011;6(3):164-84
34. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain- IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987;21(1):123-39
35. Chen CP, Alder JT, Bray L, et al. Post synaptic 5HT1A and 5HT 2A receptors are increased in Parkinson's disease neocortex. Ann NY Acad Sci 1998;861:288-9
36. Titeler M, Lyo RA, Glennon RA. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site-of-action for LSD and phenylisopropylamine hallucinogens. Psychopharmaco(Berl) 1988;94(2):213-16
37. Nordstrom AL, Mansson M, Jovanovic H, et al. PET analysis of the 5HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharmacol 2008;11(2):163-71
38. Vanover KE, Robbins-Weiler D, Wilbraham DG, et al. Pharmacokinetics, tolerability and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. J Clin Pharmacol 2007;47(6):704-14
39. Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin 2A Receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010;35(4):881-92
40. Friedman JH, Ravina B, Mills R, et al. Pimavanserin Phase III PDP results: ACP-103-012. Amer Acad Neurol; Toronto, Canada; 2010
41. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patient with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
42. Vanover KE, Betz AJ, Weber SM, et al. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav 2008;90(4):540-4; (5 cynomolgus monkeys